For latest News and updates
Aug 3, 2020
Renal cell carcinoma (RCC) is one of the most common malignancies. The immunogenomic landscape signature significantly correlates with the progression and prognosis of RCC. Novel therapeutic targets and prognostic indices in RCC...
Read MoreAug 3, 2020
Renal cell cancer (RCC) is the third most diagnosed genitourinary malignancy in the world. Nearly a half of the diagnoses and 60% of related deaths occur in low-middle income countries (LMs), where prognosis is generally poor....
Read MoreAug 3, 2020
The therapeutic options for castration resistance prostate cancer (CRPC) are still limited. Natural bioactive compounds were shown to possess pro-death properties in different tumors. We previously reported that δ-tocotrienol...
Read MoreAug 3, 2020
Moderate hypofractionated radiotherapy (HypoRT) is an attractive alternative to conventionally fractionated radiotherapy for prostate cancer. However, most studies using HypoRT only included the prostate as the target volume. We...
Read MoreAug 3, 2020
We compared the learning curve and pathologic and functional outcomes of retropubic radical prostatectomy (RRP) and robotic-assisted radical prostatectomy (RARP) performed during the same time period by a novice to identify how...
Read MoreAug 3, 2020
This Phase Ib study explored combination dosing of the allosteric MEK1/2 inhibitor cobimetinib and the ATP-competitive pan-AKT inhibitor ipatasertib.Patients with advanced solid tumors were enrolled to two dose escalation arms,...
Read MoreAug 3, 2020
Ovarian Cancer (OVCA) is the most occurring gynecological cancer worldwide, often diagnosed at a later stage and ultimate results in a high death rate. To overcome this serious health concern, it is important to understand the...
Read MoreAug 3, 2020
The current work studied the mechanism(s) and ability by which date palm (Phoenix dactylifera L.) fruit extract (DPE) inspired a glucose-lowering impact in rats suffering from diabetes. Forty-eight albino rats were divided into...
Read MoreAug 3, 2020
Myocyte enhancer factor-2B (MEF2B) has the unique capability of binding to its DNA target sites with a degenerate motif, while still functioning as a gene-specific transcriptional regulator. Identifying its DNA targets is...
Read More